Idaho. The specific exemption ends on September 30, 1979.

FOR FURTHER INFORMATION CONTACT:

Emergency Response Section, Registration Division (TS-767), Office of Pesticide Programs, EPA, 401 M Street, SW., Room E-315, Washington, D.C. 20460. Telephone: 202/755-4851.

SUPPLEMENTARY INFORMATION: According to the Applicant, a recovery project for restoring the endangered whooping crane population began in 1975 at the Grays Lake National Wildlife Refuge in Idaho. It appears that the recovery program has been successful except for the predation of eggs and chicks; approximately 50% or more of eggs and chicks have been lost to coyotes. According to the Applicant, control methods such as calling, trapping, and aerial hunting have failed to provide adequate control. Failure to control this predator will result in a setback to the recovery program or its end. There is no registered pesticide for controlling coyotes preying on wildlife populations.

A 1972 Presidential Order (Executive Order 11643) prohibits the use of chemical toxicants, such as the sodium cyanide-loaded M-44 device, on Federal lands except in emergency conditions. One of these conditions is for protection of one or more wildlife species threatened with extinction or likely within the foreseeable future to become so threatened. The U.S. Fish and Wildlife Service has the responsibility for restoration of endangered species under the Endangered Species Act of 1973. Since the whooping crane is an endangered species, there would be compliance with the Presidential Order. In addition, the EPA has issued a registration to the Applicant for the use of the M-44 device to control coyotes, foxes, and feral dogs which prey upon livestock. Thus, issuance of the specific exemption is justified from the standpoint that the M-44 device is being employed under emergency conditions and by a qualified Agency experienced in the use of this device for predator control.

Adverse effects from the use of the sodium cyanide-loaded M-44 device in the Grays Lake National Wildlife Refuge area are unlikely. This Refuge consists of approximately 15,000 acres of marsh and upland, and is primarily a waterfowl refuge area. The M-44 device will be placed on only 500 acres in this Refuge and only for a limited period of time (140 days). Coyote control is considered necessary particularly because of the high avian population; thus, the use of the M-44 device here would also fit into the overall wildlife management program. Since Refuge personnel and one grazier are the only persons permitted on the site, the chances of humans accidentally discharging the M-44 devices are remote.

After reviewing the application and other available information, EPA has determined that (a) an emergency situation involving an endangered species has been found to exist; (b) there are no alternative means of control, taking into account the efficacy and hazard; (c) significant environmental problems may result if the coyotes are not removed from the Grays Lake National Wildlife Refuge; and (d) the time available for action to mitigate the problems posed is insufficient for a pesticide to be registered for this use. Accordingly, the Applicant has been granted a specific exemption to use the pesticide noted above until September 30, 1979, to the extent and in the manner set forth in the application. The specific exemption is also subject to the following conditions:

1. A maximum of 20 M-44 devices and 40 sodium cyanide capsules containing approximately 35.51 grams of sodium cyanide are authorized;

2. The M-44 devices are to be placed on 500 acres of land at Grays Lake National Wildlife Refuge in Idaho;

3. Only trained Fish and Wildlife personnel shall hand place the M-44 devices;

4. All unused sodium cyanide capsules shall be recovered at the end of the season;

5. All precautions shall be taken to avoid or minimize hazards to nontarget species that may result from this program;

6. All applicable label precautions for M-44 cyanide capsules (EPA Reg. No. 6704-75) including the posting of warning signs must be adhered to;

7. Any adverse effects resulting from the use of M-44 devices in connection with this specific exemption must be reported to the EPA immediately; and

8. A report summarizing the results of this program must be submitted to the EPA by December 31, 1979.

(Sec. 18, Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), as amended in 1972, 1975, and 1978 (92 Stat. 819; 7 U.SC. 136))

Dated: March 23, 1979.

EDWIN L. JOHNSON,
Deputy Assistant Administrator for Pesticide Programs.

[FR Doc. 79-9815 Filed 3-29-79; 8:45 am]

[6560-01-M]

[FRL 1087-4; OPP-30148A]

PESTICIDE PROGRAMS

Approval of Application to Register Pesticide Product Containing New Active Ingredient

On May 18, 1978, notice was given (43 FR 21505) that Hoffman-La Roche, Inc., 340 Kingsland St., Nutley, NJ 07110, had filed an application (EPA File Symbol 35977-R) with the Environmental Protection Agency (EPA) to register the pesticide product Atrinal Liquid Concentrate containing 18.5% of the active ingredient dikegulac sodium (sodium salt of 2,3:4,6-bis-*O*-(1 - methylethylidene) -*α*- *L* - xylo - 2-hexulofuranosonic acid) which was not previously registered at the time of submission.

This application was approved on March 7, 1979 and the product has been assigned EPA Registration No. 35977-1. Atrinal Liquid Concentrate is classified for general use as a plant regulator. A copy of the approved label and list of data references used to support registration are available for public inspection in the office of the Federal Register Section, Program Support Division (TS-757), Office of Pesticide Programs, Rm. 401 East Tower, 401 M St., SW, Washington, DC 20460. The data and other scientific information used to support registration, except for the material specifically protected by Section 10 of the Federal insecticide, Fungicide, and Rodenticide Act (FIFRA) as amended in 1972, 1975, and 1978 (92 Stat. 819; 7 U.S.C. 136) will be available for public inspection in accordance with Section 3(c)(2) of FIFRA, within 30 days after the registration date of March 7, 1979. Requests for data must be made in accordance with the provisions of the Freedom of Information Act and must be addressed to the Freedom of Information Office (A-101), EPA, 401 M St., SW, Washington, DC 20460. Such requests should: (1) identify the product by name and registration number and (2) specify the data or information desired.

Dated: March 21, 1979.

EDWIN L. JOHNSON,
Deputy Assistant Administrator for Pesticide Programs.

[FR Doc. 79-9817 Filed 3-29-79; 8:45 am]

[6712-01-M]

FEDERAL COMMUNICATIONS COMMISSION

FOURTH MEETING OF THE ADVISORY COMMITTEE ON CABLE SIGNAL LEAKAGE

Meeting

Pursuant to Section 10 of the Federal Advisory Committee Act, notice of a meeting of the Advisory Committee on Cable Signal Leakage is hereby given. The meeting will be at 10:00 AM on Tuesday, April 17, 1979, in Room A-110 of the Federal Communications Commission offices at 1229-20th Street, NW., Washington, D.C.

The agenda are as follows:

(1) Review of ground and airspace measurements and analysis;

(2) Review of draft Report.

Any member of the public may attend or file a written statement with the Commission either before or after the meeting. Any member of the public wishing to make an oral statement must consult with the Committee prior to the meeting. Inquiries may be directed to Mr. Robert S. Powers, FCC, 2025 M Street, NW., Washington, D.C. 20554, telephone 202/632-9797.

FEDERAL COMMUNICATIONS COMMISSION,
WILLIAM J. TRICARICO,
Secretary.

[FR Doc. 79-9738 Filed 3-29-79; 8:45 am]

[6730-01-M]

FEDERAL MARITIME COMMISSION

DETERMINATION

The Federal Maritime Commission hereby gives notice that the following agreements have been submitted to the Commission for determination of whether or not they are subject to the filing and approval requirements of section 15 of the Shipping Act, 1916, as amended (39 Stat. 733, 75 Stat. 763, 46 U.S.C. 814), and, if it is determined that the agreements require approval, whether it would be appropriate to exempt the agreements from the approval requirements of section 15 pursuant to section 35 of the Shipping Act.

Although these agreements may not be subject to section 15 of the Shipping Act, interested parties are given an opportunity to comment on this notice if they so desire. Interested parties may inspect and obtain copies of the agreements at the Washington Office of the Federal Maritime Commission, 1100 L Street, NW., Room 10423, or may inspect the agreements at the Field Offices located at New York, N.Y.; New Orleans, Louisiana; San Francisco, California; Chicago, Illinois; and San Juan, Puerto Rico. Interested parties may submit comments on the agreements to the Secretary, Federal Maritime Commission, Washington, D.C. 20573, on or before April 19, 1979.

AGREEMENTS: Vessel Charter Agreements between Sea-Land Service, Inc. and Puerto Rico Maritime Shipping Authority.

FILING PARTY: Donald J. Brunner, Esquire, Ragan & Mason, 900 Seventeenth Street, NW., Washington, D.C. 20006.

SUMMARY: These agreements provide that Puerto Rico Maritime Shipping Authority, as Owner, agrees to let, and Sea-Land Service, Inc., as Charterer, agrees to time-charter, the vessels named HUMACAO and GUYAMA, to be employed by the Charterer in the trades between United States mainland ports or between U.S. mainland ports and ports in Europe, according to the terms, conditions and the extent set forth in the charter agreements. The duration of the charter agreements are for a two-month period with Sea-Land having the option of extending the charters for three further two-month periods.

Dated: March 27, 1979.

By order of the Federal Maritime Commission.

FRANCIS C. HURNEY,
Secretary.

[FR Doc. 79-9737 Filed 3-29-79; 8:45 am]

[1610-01-M]

GENERAL ACCOUNTING OFFICE

REGULATORY REPORTS REVIEW

Receipt of Report Proposal

The following request for clearance of a report intended for use in collecting information from the public was received by the Regulatory Reports Review Staff, GAO, on March 26, 1979. See 44 U.S.C. 3512 (c) and (d). The purpose of publishing this notice in the FEDERAL REGISTER is to inform the public of such receipt.

The notice includes the title of the request received; the name of the agency sponsoring the proposed collection of information; the agency form number, if applicable; and the frequency with which the information is proposed to be collected.

Written comments on the proposed FCC request are invited from all interested persons, organizations, public interest groups and affected businesses. Because of the limited amount of time GAO has to review the proposed request, comments (in triplicate) must be received on or before April 17, 1979, and should be addressed to Mr. John M. Lovelady, Assistant Director, Regulatory Reports Review, United States General Accounting Office, Room 5106, 441 G Street, NW., Washington, DC 20548.

Further information may be obtained from Patsy J. Stuart of the Regulatory Reports Review Staff, 202-275-3532.

FEDERAL COMMUNICATIONS COMMISSION

The FCC requests clearance of revised instructions to Form 395, Annual Employment Report. Form 395 is used to monitor and enforce FCC Rules and Regulations pertaining to Equal Employment Opportunities (EEO) and is required by §§ 1.612, 73.125, 1.815(a), 21.307, and 23.55 of the Commission's Rules and Regulations. Since the Equal Employment Opportunity Commission does not collect data from firms with less than 100 employees, the FCC feels that they need to collect data from firms employing less than 100 as this constitutes a significant percentage of firms operating in the communications industry and cannot be omitted if the Commission is to effectively monitor EEO practices. The instructions associated with Form 395 are being revised to better define job categories associated with the broadcast industry. The FCC estimates respondent burden for Form 395 will average 63 minutes per response and that there are approximately 10,700 broadcasters and common carriers who report annually.

FCC First Report and Order, Docket No. 21474, adopted December 21, 1978, and released January 29, 1979, promulgated the revisions which have been incorporated in the instructions to Form 395. Although the Order specified that the revisions become effective on April 1, 1979, this effective date is contingent upon FCC's compliance with 44 U.S.C. 3512 which precludes the collection of information from 10 or more persons until the Comptroller General has had the opportunity to advise that the information is not presently available from other Federal sources and that the proposed instructions to Form 395 are consistent with the provisions of section 3512. This notice represents the beginning of our review.

NORMAN F. HEYL,
Regulatory Reports Review Officer.

[FR Doc. 79-9762 Filed 3-29-79; 8:45 am]

[1610-01-M]

REGULATORY REPORTS REVIEW

Receipt of Report Proposal

The following request for clearance of a report intended for use in collecting information from the public was

received by the Regulatory Reports Review Staff, GAO, on March 26, 1979. See 44 U.S.C. 3512(c) and (d). The purpose of publishing this notice in the FEDERAL REGISTER is to inform the public of such receipt.

The notice includes the title of the request received; the name of the agency sponsoring the proposed collection of information; the agency form number, if applicable; and the frequency with which the information is proposed to be collected.

Written comments concerning the reporting burden and duplication imposed by the proposed FCC forms and the forms' instructions are invited from all interested persons, organizations, public interest groups and affected businesses. Because of the limited amount of time GAO has to review the proposed request, and in an effort to expedite the clearance review, comments (in triplicate) must be received on or before April 13, 1979, and should be addressed to Mr. John M. Lovelady, Assistant Director, Regulatory Reports Review, United States General Accouting Office, Room 5106, 441 G Street, NW, Washington, DC 20548.

Further information may be obtained from Patsy J. Stuart of the Regulatory Reports Review Staff, 202-275-3532.

FEDERAL COMMUNICATIONS COMMISSION

The FCC requests clearance of new Forms 199-A and 199-B, Over $20 Fee Refund Request Forms, and instructions. The Fee Refund Program was mandated by the United States Circuit Court of Appeals on December 16, 1976. Forms 199-A and 199-B will be used by the FCC to collect data to verify the identification of the applicant, the amount and purpose for which the fee was paid, to make a proper refund, to enable the original processing bureau/office to locate records, and to ensure that refund checks are forwarded to the correct address. The FCC estimates that approximately 150,000 refund requests will be received and that respondent burden will average one hour and fifty minutes per application.

NORMAN F. HEYL,
Regulatory Reports Review Officer.

[FR Doc. 79-9763 Filed 3-29-79; 8:45 am]

[4110-03-M]

DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE

Food and Drug Administration

[Docket No. 79F-0058]

ARMAK CO.

Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Armak Company has filed a petition proposing that the food additive regulations be amended to provide for the safe use of an anionic polyurethane as a component of paper and paperboard in contact with dry food.

FOR FURTHER INFORMATION CONTACT:

John J. McAuliffe, Bureau of Foods (HFF-334), Food and Drug Administration, Department of Health, Education, and Welfare, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 8B3371) has been filed by Armak Co., 300 S. Wacker Dr., Chicago, IL 60606 proposing that § 176.180 *Components of paper and paperboard in contact with dry food* (21 CFR 176.180) be amended to provide for the safe use of anionic polyurethane, produced by reacting the preliminary adduct formed from the reaction of glyceryl monostearate and toluene diisocyanate with not more than 10 mole percent N-methyldiethanolamine and not less than 90 mole percent dimethylolpropionic acid.

The agency has determined that the proposed action falls under 21 CFR 25.1(f)(1)(v) and is exempt from the requirement of an environmental impact anyalysis report, and that no environmental impact statement is necessary.

Dated: March 21, 1979.

ROBERT M. SCHAFFNER,
Acting Director, Bureau of Foods.

[FR Doc. 79-9407 Filed 3-29-79; 8:45 am]

[4110-03-M]

[Docket No. 75N-0184; DESI 597, 3265, 4681, & 10837]

CERTAIN DRUG PRODUCTS CONTAINING AN ANTICHOLINERGIC OR ANTISPASMODIC IN COMBINATION WITH A SEDATIVE OR TRANQUILIZER; ANTICHOLINERGIC AND ANTISPASMODIC DRUGS ALONE

Withdrawal of Approval of New Drug Applications

AGENCY: Food and Drug Administration (FDA).

ACTION: Notice.

SUMMARY: This notice withdraws approval of certain drug products containing an anticholinergic or antispasmodic in combination with a sedative or tranquilizer, and others containing an anticholinergic or antispasmodic drug alone. The basis of the action is that the drug products lack substantial evidence of effectiveness.

EFFECTIVE DATE: April 9, 1979.

ADDRESS: Requests for an opinion of the applicability of this notice to a specific product should be identified with the reference number DESI 597, 3265, 4681, or 10837, as appropriate, and directed to the Division of Drug Labeling Compliance (HFD-310), Bureau of Drugs, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT:

Herbert Gerstenzang, Bureau of Drugs (HFD-32), Food and Drug Administration, Department of Health, Education, and Welfare, 5600 Fishers Lane, Rockville, MD 20857, 301-443-3650.

SUPPLEMENTARY INFORMATION: In a notice of opportunity for hearing published in the FEDERAL REGISTER of August 19, 1977 (42 FR 41917), the Director of the Bureau of Drugs proposed to issue an order withdrawing approval of the subject drugs. The basis of the proposed order was that the drugs lack substantial evidence of effectiveness for their labeled indications.

In response to the August 19, 1977, notice, a request for a hearing was submitted for the following drug product:

Trocinate Tablets containing thiphenamil hydrochloride; William P. Poythress & Co., 899 North Wilmot Rd., Tucson, AZ 85711; part of NDA 6-098. The drug product is not affected by this notice but will be the subject of a future notice.

In response to a notice published in the FEDERAL REGISTER of November 11, 1975 (40 FR 52649), Knoll Pharmaceutical Co. had requested a hearing for Octin Tablets containing isomethep-

tene mucate and Octin Solution containing isometheptene hydrochloride, for the indication "treatment of migraine headache (NDA 6-420)." Because the request is still under review, the drug products are not affected by this notice but will also be the subject of a future notice.

A notice was published in the FEDERAL REGISTER of March 9, 1979 (44 FR 13079), withdrawing approval of NDA 4-298 for Metropine Phenobarbital Tablets containing methylatropine nitrate and phenobarbital; formerly marketed by Pennwalt Prescription Products, Division Pennwalt Corp., P.O. Box 1710, Rochester, NY 14603. Approval was withdrawn on the ground of failure to submit required reports under section 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)). At that time no final effectiveness classification of the drug had yet been made. The conclusions described herein are applicable to that drug product.

No other application holder or any other person has filed a written appearance of election as provided for by the August 19, 1977, notice. The failure to file such an appearance constitutes election by such persons not to avail themselves of the opportunity for a hearing, and therefore approval of the following new drug applications is now being withdrawn.

DESI 597

NDA 8-910; that part of the NDA pertaining to Tricoloid and Phenobarbital Tablets containing tricyclamol chloride and phenobarbital; formerly marketed by Burroughs Wellcome & Co., Inc., 3030 Cornwallis Rd., Research Triangle Park, NC 27709.

NDA 9-427; that part of the NDA pertaining to Piptal-PHB Tablets, containing pipenzolate bromide and phenobarbital; Merrell-National Laboratories, Division of Richardson-Merrell, Inc., P.O. Box 15260, Cincinnati, OH 45215.

NDA 8-919; that part of the NDA pertaining to Co-Elorine 100 Pulvules containing tricyclamol chloride and amobarbital; formerly marketed by Eli Lilly & Co., P.O. Box 618, Indianapolis, IN 46206.

NDA 9-288; Centrine Tablets with Phenobarbital containing aminopentamide sulfate and phenobarbital; formerly marketed by Bristol Laboratories, Division of Bristol-Myers Co., P.O. Box 657, Syracuse, NY 13201.

NDA 8-885; that part of the NDA pertaining to Centrine Elixir with Phenobarbital containing aminopentamide sulfate and phenobarbital; formerly marketed by Bristol Laboratories.

NDA 7-390; that part of the NDA pertaining to Banthine with Phenobarbital Tablets containing methantheline bromide and phenobarbital; formerly marketed by G. D. Searle & Co., P.O. Box 5110, Chicago, IL 60680.

NDA 9-032; that part of the NDA pertaining to Monomeb Tablets containing penthienate bromide and mephobarbital; formerly marketed by Winthrop Laboratories, 90 Park Ave., New York, NY 10016.

NDA 12-741; Nactisol Tablets containing poldine methylsulfate and sodium butabarbital; formerly marketed by McNeil Laboratories Inc., Camp Hill Rd., Fort Washington, PA 19034.

NDA 6-471; that part of the NDA pertaining to Profenil Phenobarbital Tablets containing alverine citrate and phenobarbital; Chemical Management Services, Division of Chemetron Corp., 111 E. Wacker Dr., Chicago, IL 60601.

NDA 8-492; that part of the NDA pertaining to Antrenyl-Phenobarbital Tablets containing oxyphenonium bromide and phenobarbital; Ciba Pharmaceutical Co., Division of Ciba-Geigy Corp., 556 Morris Ave., Summit, NJ 07901.

NDA 10-599; that part of the NDA pertaining to Tral with Phenobarbital Tablets containing hexocyclium methylsulfate and phenobarbital; Abbott Laboratories, 14th and Sheridan Rd., N. Chicago, IL 60064.

NDA 8-942; that part of the NDA pertaining to Pamine PB Tablets containing methscopolamine bromide and phenobarbital; The Upjohn Co., 7171 Portage Rd., Kalamazoo, MI 49002.

NDA 6-098; that part of the NDA pertaining to Trocinate with Phenobarbital Tablets containing thiphenamil hydrochloride and phenobarbital; formerly marketed by William P. Poythress & Co.

DESI 4681

NDA 8-829; Prantal with Phenobarbital Tablets containing diphemanil methylsulfate and phenobarbital; Schering Corp., Galloping Hill Rd., Kenilworth, NJ 07033.

DESI 10837

NDA 12-070; Daritran Tablets containing oxyphencyclimine hydrochloride and meprobamate; formerly marketed by Pfizer Laboratories, Division Pfizer Inc., 235 E. 42d St., New York, NY 10017.

DESI 3265

NDA 5-695; that part of the NDA pertaining to Profenil Tablets containing alverine citrate; Chemical Management Services, Division of Chemetron Corp.

ANDA 80-634; Spacolin Tablets containing alverine citrate; Philips Roxane Laboratories, Inc., 330 Oak St., Columbus, OH 43216.

Other drug products named in the August 19, 1977, notice are not affected by this action. A notice published in the FEDERAL REGISTER of June 20, 1978 (43 FR 26489), rescinded the August 19, 1977, notice insofar as it pertained to them.

Any drug product that is identical, related, or similar to a drug product named above and is not the subject of an approved new drug application is covered by the new drug applications reviewed and is subject to this notice (21 CFR 310.6). Any person who wishes to determine whether a specific product is covered by this notice should write to the Division of Drug Labeling Compliance (address given above).

The Director of the Bureau of Drugs, under the Federal Food, Drug, and Cosmetic Act (sec. 505, 52 Stat. 1052-1053, as amended (21 U.S.C. 355)), and under authority delegated to him (21 CFR 5.82), finds that, on the basis of new information before him with respect to the drug products, evaluated together with the evidence available to him when the applications were approved, there is a lack of substantial evidence that the drug products will have the effect they purport or are represented to have under the conditions of use prescribed, recommended, or suggested in their labeling.

Therefore, pursuant to the foregoing finding, approval of the new drug applications (or as indicated above, those parts of the applications providing for the drug products listed) and all amendments and supplements thereto, is withdrawn effective April 9, 1979.

Shipment in interstate commerce of the above products or of any identical, related, or similar product that is not the subject of an approved new drug application will then be unlawful.

Dated: March 22, 1979.

J. RICHARD CROUT,
Director, Bureau of Drugs.

[FR Doc. 79-9268 Filed 3-29-79; 8:45 am]

[4110-03-M]

[Docket No. 79N-0011]

CHLORTETRACYCLINE SOLUBLE TABLETS FOR ANIMAL USE

Drug Efficacy Study Implementation; Followup Notice and Opportunity for Hearing

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The agency announces the effective indications for which chlortetracycline soluble tablets for animal use may be marketed and offers an opportunity for hearing on indications lacking substantial evidence of effectiveness.

DATES: Written requests for hearing, comments in response to this notice, and supplements to new animal drug